161 related articles for article (PubMed ID: 35422023)
1. Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo.
Lisinski A; Hieronymus F; Nilsson S; Eriksson E
Transl Psychiatry; 2022 Apr; 12(1):160. PubMed ID: 35422023
[TBL] [Abstract][Full Text] [Related]
2. Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Lancet Psychiatry; 2019 Sep; 6(9):745-752. PubMed ID: 31303567
[TBL] [Abstract][Full Text] [Related]
3. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression.
Hieronymus F; Lisinski A; Nilsson S; Eriksson E
Mol Psychiatry; 2018 Aug; 23(8):1731-1736. PubMed ID: 29155804
[TBL] [Abstract][Full Text] [Related]
5. Item-based analysis of the effects of duloxetine in depression: a patient-level post hoc study.
Lisinski A; Hieronymus F; Näslund J; Nilsson S; Eriksson E
Neuropsychopharmacology; 2020 Feb; 45(3):553-560. PubMed ID: 31521062
[TBL] [Abstract][Full Text] [Related]
6. Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.
Hieronymus F; Emilsson JF; Nilsson S; Eriksson E
Mol Psychiatry; 2016 Apr; 21(4):523-30. PubMed ID: 25917369
[TBL] [Abstract][Full Text] [Related]
7. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
[TBL] [Abstract][Full Text] [Related]
8. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
11. Do side effects of antidepressants impact efficacy estimates based on the Hamilton Depression Rating Scale? A pooled patient-level analysis.
Hieronymus F; Lisinski A; Eriksson E; Østergaard SD
Transl Psychiatry; 2021 Apr; 11(1):249. PubMed ID: 33907188
[TBL] [Abstract][Full Text] [Related]
12. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors.
Hieronymus F; Nilsson S; Eriksson E
Transl Psychiatry; 2016 Jun; 6(6):e834. PubMed ID: 27271860
[TBL] [Abstract][Full Text] [Related]
13. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Sun Y; Liang Y; Jiao Y; Lin J; Qu H; Xu J; Zhao C
BMJ Open; 2017 Aug; 7(8):e016499. PubMed ID: 28775189
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
16. Incidence of early anxiety aggravation in trials of selective serotonin reuptake inhibitors in depression.
Näslund J; Hieronymus F; Emilsson JF; Lisinski A; Nilsson S; Eriksson E
Acta Psychiatr Scand; 2017 Oct; 136(4):343-351. PubMed ID: 28859218
[TBL] [Abstract][Full Text] [Related]
17. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
19. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of Chinese randomized clinical trials of SSRI treatment of depression.
Zhang Y; Becker T; Ma Y; Koesters M
BMC Psychiatry; 2014 Aug; 14():245. PubMed ID: 25159460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
